



Release No 175

25 October 2005

## **EU Commission inspection**

Representatives from the EU Commission today conducted an inspection at the premises of H. Lundbeck. The purpose was to identify whether H. Lundbeck has misused a dominant position or has been involved in anticompetitive agreements in the markets for antidepressant drugs.

Lundbeck has nothing to hide and gave the EU Commission representatives full access to all documents.

The content of this release will have no influence on the Lundbeck Group's expectations for the financial result for 2005.

## **Lundbeck contacts**

Steen Juul Jensen  
Vice President  
+45 36 43 30 06

Media contact Helle Hedegaard Juhl  
Media Relations Officer  
+45 36 43 41 68

Investor contact Jacob Tolstrup  
Investor Relations Manager  
+45 36 43 30 79

---

## **About Lundbeck**

H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2004, the company's revenue was DKK 9.7 billion (approx. EUR 1.3 billion). The number of employees is approx. 5,000. For further information, visit [www.lundbeck.com](http://www.lundbeck.com)